← Back to Screener
Arrowhead Research Corporation (ARWR)
Price$69.25
Favorite Metrics
Price vs S&P 500 (26W)84.14%
Price vs S&P 500 (4W)14.06%
Market Capitalization$9.70B
All Metrics
P/CF (Annual)54.01x
Book Value / Share (Quarterly)$4.14
P/TBV (Annual)10.19x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)50.52%
Cash Flow / Share (Quarterly)$2.34
Price vs S&P 500 (YTD)0.38%
Net Profit Margin (TTM)18.54%
EPS (TTM)$1.54
10-Day Avg Trading Volume1.90M
EPS Excl Extra (TTM)$1.54
Revenue Growth (5Y)56.63%
EPS (Annual)$-0.01
ROI (Annual)-0.15%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-3428.42%
Cash / Share (Quarterly)$6.66
P/E Basic Excl Extra (TTM)47.94x
Revenue Growth QoQ (YoY)10461.32%
ROA (Last FY)-0.12%
Revenue Growth TTM (YoY)43539.24%
EBITD / Share (TTM)$2.40
ROE (5Y Avg)-95.58%
Operating Margin (TTM)27.55%
Cash Flow / Share (Annual)$1.16
P/B Ratio17.06x
P/B Ratio (Quarterly)15.86x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)9.24x
Net Interest Coverage (TTM)1.99x
ROA (TTM)13.61%
EV / EBITDA (TTM)30.45x
EPS Incl Extra (Annual)$-0.01
Current Ratio (Annual)4.86x
Quick Ratio (Quarterly)3.33x
3-Month Avg Trading Volume2.69M
52-Week Price Return516.10%
EV / Free Cash Flow (Annual)64.22x
P/E Incl Extra (TTM)47.94x
Revenue / Employee (TTM)$2
Tangible BV / Share (Quarterly)$4.09
P/S Ratio (Annual)11.69x
Asset Turnover (Annual)0.60x
52-Week High$76.76
Operating Margin (5Y Avg)-3436.30%
EPS Excl Extra (Annual)$-0.01
CapEx CAGR (5Y)13.56%
Tangible BV CAGR (5Y)0.57%
26-Week Price Return91.03%
Quick Ratio (Annual)4.81x
13-Week Price Return4.53%
Total Debt / Equity (Annual)1.34x
Current Ratio (Quarterly)3.38x
Enterprise Value$10,075.591
Revenue / Share Growth (5Y)47.98%
Asset Turnover (TTM)0.73x
Book Value / Share Growth (5Y)-5.30%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)0.00x
Pretax Margin (Annual)6.21%
Cash / Share (Annual)$6.76
3-Month Return Std Dev49.55%
Net Income / Employee (TTM)$0
ROE (Last FY)-0.35%
Net Interest Coverage (Annual)6.01x
EPS Basic Excl Extra (Annual)$-0.01
P/FCF (TTM)20.24x
Receivables Turnover (TTM)9.86x
EV / Free Cash Flow (TTM)31.29x
Total Debt / Equity (Quarterly)1.02x
EPS Incl Extra (TTM)$1.54
Receivables Turnover (Annual)343.86x
ROI (TTM)17.33%
P/S Ratio (TTM)8.89x
Pretax Margin (5Y Avg)-3499.99%
Revenue / Share (Annual)$6.20
Tangible BV / Share (Annual)$3.38
Price vs S&P 500 (52W)481.47%
P/E Ratio (TTM)47.94x
Year-to-Date Return4.31%
5-Day Price Return3.84%
EPS Normalized (Annual)$-0.01
ROA (5Y Avg)-24.96%
Net Profit Margin (Annual)-0.20%
Month-to-Date Return10.45%
Cash Flow / Share (TTM)$-1.62
EBITD / Share (Annual)$0.95
Operating Margin (Annual)11.86%
LT Debt / Equity (Annual)1.25x
P/CF (TTM)28.58x
ROI (5Y Avg)-43.92%
P/E Excl Extra (TTM)47.94x
LT Debt / Equity (Quarterly)0.95x
EPS Basic Excl Extra (TTM)$1.54
P/TBV (Quarterly)16.04x
P/B Ratio (Annual)10.04x
Pretax Margin (TTM)23.37%
Book Value / Share (Annual)$3.43
Price vs S&P 500 (13W)2.15%
Beta1.23x
P/FCF (Annual)61.81x
Revenue / Share (TTM)$7.75
ROE (TTM)36.12%
52-Week Low$10.92
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.95
3.95
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ARWRArrowhead Research Corporation | 8.89x | 43539.24% | — | — | $69.25 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Arrowhead Pharmaceuticals is a biotechnology company developing genetic medicines to treat diseases caused by protein overproduction. Its pipeline spans cardiovascular, cardiometabolic, pulmonary, central nervous system, liver, muscular, and complement-mediated disease areas, with the majority of its product candidates concentrated in liver disease treatments.